Possible involvement of inositol phosphoglycan-P in human parturition

Journal of Reproductive Immunology

Volumn 59, Issue 2, 2003, Pages 267-275

  Paine, M A ^a   Rodeck, C H ^a   Williams, P J ^a   Rademacher, T W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Inositolphosphoglycans; IPG; Pre eclampsia; Preterm labour

Indexed keywords

GLYCAN DERIVATIVE; INOSITOL PHOSPHOGLYCAN P; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

CHILDBIRTH; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABOR INDUCTION; PLACENTA; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; SECOND MESSENGER; THIRD TRIMESTER PREGNANCY; URINALYSIS; URINE LEVEL;

EID: 0042168705     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0378(03)00053-6     Document Type: Conference Paper

References (21)

1. Anderson R.G. The caveolae membrane system. Annu. Rev. Biochem. 67:1998;199-225.
2. Attwood H.D., Park W.W. Embolism to the lungs by trophoblast. J. Obstet. Gynaecol. Br. Commonw. 68:1961;611-617.
3. Caro H.N., Kunjara S., Rademacher T.W., Leon Y., Jones D.R., Avila M.A., Varela-Nieto I. Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver. Biochem. Mol. Med. 61:1997;214-228.
4. Davidson B.J., Murray R.D., Challis J.R., Valenzuela G.J. Estrogen, progesterone, prolactin, prostaglandin E2, prostaglandin F2 alpha, 13,14-dihydro-15-keto-prostaglandin F2 alpha, and 6-keto-prostaglandin F1 alpha gradients across the uterus in women in labor and not in labor. Am. J. Obstet. Gynecol. 157:1987;54-58.
5. Deborde, S., Paine, M., Schofield, J.N., Rademacher, T.W., 2003. Placental GPI-PLD is of maternal origin and its GPI substrate is absent from placenta of pregnancies associated with preeclampsia, J. Reprod. Immunol. 59, 277-294.
6. Ducibella T., Huneau D., Angelichio E., Xu Z., Schultz R.M., Kopf G.S., Fissore R., Madoux S., Ozil J.P.15-10-. Egg-to-embryo transition is driven by differential responses to Ca(2+) oscillation number. Dev. Biol. 250:2002;280-291.
7. Kunjara S., Wang D.Y., Greenbaum A.L., McLean P., Kurtz A., Rademacher T.W. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes. Mol. Genet. Metab. 68:1999;488-502.
8. Kunjara S., Greenbaum A.L., Wang D.Y., Caro H.N., McLean P., Redman C.W., Rademacher T.W. Inositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: evidence for a significant regulatory role in preeclampsia at placental and systemic levels. Mol. Genet. Metab. 69:2000;144-158.
9. Kunjara S., Wang D.Y., McLean P., Greenbaum A.L., Rademacher T.W. Inositol phosphoglycans and the regulation of the secretion of leptin: in vitro effects on leptin release from adipocytes and the relationship to obesity. Mol. Genet. Metab. 70:2000;61-68.
10. Kunjara, S., Greenbaum, A.L., McLean, P., Rademacher, T.W., 2003. Inositol phosphoglycans; a fine tuning mechanism to target calcium responses in the cell. Nature (submitted for publication).
11. Kvirkvelia N., Vojnovic I., Warner T.D., Athie-Morales V., Free P., Rayment N., Chain B.M., Rademacher T.W., Lund T., Roitt I.M., Delves P.J. Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. Clin. Exp. Immunol. 127:2002;263-269.
12. Lockwood C.J. Predicting premature delivery - no easy task. New Engl. J. Med. 346:2002;282-284.
13. Masuzaki H., Ogawa Y., Sagawa N., Hosoda K., Matsumoto T., Mise H., Nishimura H., Yoshimasa Y., Tanaka I., Mori T., Nakao K. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat. Med. 3:1997;1029-1033.
14. Mise H., Sagawa N., Matsumoto T., Yura S., Nanno H., Itoh H., Mori T., Masuzaki H., Hosoda K., Ogawa Y., Nakao K. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. J. Clin. Endocrinol. Metab. 83:1998;3225-3229.
15. Parpal S., Gustavsson J., Stralfors P. Isolation of phosphooligosaccharide/phosphoinositol glycan from caveolae and cytosol of insulin-stimulated cells. J. Cell. Biol. 131:1995;125-135.
16. Rademacher T.W., Caro H., Kunjara S., Wang D.Y., Greenbaum A.L., McLean P. Inositolphosphoglycan second messengers. Braz. J. Med. Biol. Res. 27:1994;327-341.
17. Sanchez-Bueno A., Greenwood M.R., Varela-Nieto I., Marrero I., Gil B., Mato J.M., Cobbold P.H. Inositol-phosphoglycan inhibits calcium oscillations in hepatocytes by reducing calcium entry. Cell Calcium. 21:1997;125-133.
18. Schofield J.N., Stephens J.W., Hurel S.J., Bell K.M., deSouza J.B., Rademacher T.W. Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats. Mol. Genet. Metab. 75:2002;154-161.
19. Shashkin P.N., Wasner H.K., Ortmeyer H.K., Hansen B.C. Prostaglandylinositol cyclic phosphate (cPIP): a novel second messenger of insulin action. Comparative analysis of two kinds of "insulin mediators" Diabetes Metab. Res. Rev. 17:2001;273-284.
20. Slattery M.M., Morrison J.J. Preterm delivery. Lancet. 360:2002;1489-1497.
21. Sleight S., Wilson B.A., Heimark D.B., Larner J. G(q/11) is involved in insulin-stimulated inositol phosphoglycan putative mediator generation in rat liver membranes: co-localization of G(q/11) with the insulin receptor in membrane vesicles. Biochem. Biophys. Res. Commun. 295:2002;561-569.